Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CRISPR Therapeutics
CRISPR Therapeutics
[video+transcript] Gene-Editing Stocks Took Stutter Steps Forward in 2018
Motley Fool
Tue, 12/18/18 - 10:34 am
gene editing
Editas
Vertex Pharmaceuticals
CRISPR Therapeutics
Sangamo BioSciences
CRISPR, MaxCyte expand partnership into immuno-oncology
Pharmaceutical Business Review
Tue, 11/13/18 - 09:47 am
CRISPR Therapeutics
MaxCyte
immuno-oncology
gene editing
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Motley Fool
Tue, 11/6/18 - 12:25 am
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test
Xconomy
Wed, 10/10/18 - 10:49 pm
CRISPR Therapeutics
Vertex Pharmaceuticals
sickle cell disease
FDA
CTX001
CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy
Xconomy
Mon, 09/17/18 - 03:18 pm
ViaCyte
stem cells
diabetes
CRISPR Therapeutics
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Motley Fool
Mon, 09/3/18 - 12:20 pm
Amarin
CRISPR Therapeutics
Geron
Vascepa
Vertex Pharmaceuticals
CTX001
JNJ
imetelstat
First CRISPR clinical trial backed by U.S. companies launches
Stat
Fri, 08/31/18 - 12:03 pm
clinical trials
CRISPR
beta thalassemia
Vertex Pharmaceuticals
CRISPR Therapeutics
Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
Motley Fool
Tue, 07/24/18 - 11:43 pm
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic
Motley Fool
Wed, 06/13/18 - 09:45 am
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May
Motley Fool
Fri, 06/8/18 - 11:59 pm
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study
Xconomy
Wed, 05/30/18 - 08:58 pm
sickle cell disease
FDA
Vertex Pharmaceuticals
CRISPR Therapeutics
CTX001
stem cells
3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate
Motley Fool
Thu, 02/15/18 - 11:08 am
Gilead Sciences
M&A
Editas
Madrigal Pharmaceuticals
CRISPR Therapeutics
Galapagos
CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values
Xconomy
Fri, 01/12/18 - 10:43 am
CRISPR
CRISPR Therapeutics
Intellia Therapeutics
Disruptor Alert: These 5 Companies Are Changing Healthcare
Motley Fool
Thu, 11/16/17 - 09:23 am
CRISPR Therapeutics
Editas Medicine
Illumina
IBM
Intellia Therapeutics
gene editing
gene sequencing
artificial intelligence
Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
Endpoints
Tue, 05/16/17 - 11:35 am
Editas
CRISPR-Cas9
CRISPR Therapeutics
Intellia Therapeutics
The CRISPR patent decision: Your six takeaways
Stat
Thu, 02/16/17 - 10:13 am
CRISPR Therapeutics
patents
CRISPR-Cas9
Broad Institute
What Happened in Biotech in 2016?
Motley Fool
Tue, 11/22/16 - 09:57 pm
biotech
M&A
biosimilars
IPOs
Editas Medicine
CRISPR Therapeutics
Pfizer
Medivation
Celgene
Juno Therapeutics
Sarepta Therapeutics
CRISPR Therapeutics Announces Pricing of Initial Public Offering
Cafepharma/Globe Newswire
Wed, 10/19/16 - 10:42 am
CRISPR Therapeutics
IPOs
CRISPR Therapeutics IPO Holds Promise With High Risk
Seeking Alpha
Tue, 10/11/16 - 09:35 am
CRISPR Therapeutics
IPOs
Gene editing star CRISPR Therapeutics files for $90M IPO
Endpoints
Fri, 09/9/16 - 09:05 pm
gene editing
CRISPR Therapeutics
IPOs
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »